S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Biden's latest bailout--terrible for America? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Biden's latest bailout--terrible for America? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Hollywood's writers strike is on the verge of ending. What happens next?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Biden's latest bailout--terrible for America? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Biden's latest bailout--terrible for America? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Hollywood's writers strike is on the verge of ending. What happens next?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Biden's latest bailout--terrible for America? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Biden's latest bailout--terrible for America? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Hollywood's writers strike is on the verge of ending. What happens next?
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Biden's latest bailout--terrible for America? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Biden's latest bailout--terrible for America? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Hollywood's writers strike is on the verge of ending. What happens next?
NASDAQ:EXEL

Exelixis (EXEL) Price Target & Analyst Ratings

$21.48
-0.10 (-0.46%)
(As of 09/22/2023 ET)
Compare
Today's Range
$21.44
$21.75
50-Day Range
$19.19
$22.74
52-Week Range
$14.87
$22.80
Volume
2.24 million shs
Average Volume
2.12 million shs
Market Capitalization
$6.84 billion
P/E Ratio
42.12
Dividend Yield
N/A
Price Target
$24.73

Exelixis Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 14 Analyst Ratings

Consensus Analyst Price Target

$24.73
15.15% Upside
High Prediction$32.00
Average Prediction$24.73
Low Prediction$18.00
TypeCurrent
9/24/22 to 9/24/23
1 Month Ago
8/25/22 to 8/25/23
3 Months Ago
6/26/22 to 6/26/23
1 Year Ago
9/24/21 to 9/24/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$24.73$24.73$25.09$29.88
Predicted Upside15.15% Upside31.26% Upside45.05% Upside44.87% Upside
Get Exelixis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.


EXEL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EXEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Exelixis Stock vs. The Competition

TypeExelixisMedical CompaniesS&P 500
Consensus Rating Score
2.64
2.66
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside15.15% Upside1,392.53% Upside629.68% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/13/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$32.00+45.12%
9/13/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Hold$23.00+4.31%
8/22/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$25.00 ➝ $29.00+35.70%
8/22/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$24.00 ➝ $27.00+26.35%
8/8/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Liu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
8/8/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$18.00-11.11%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$18.00-11.11%
8/3/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$25.00 ➝ $24.00+17.99%
8/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$21.00 ➝ $22.00+8.16%
3/9/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$23.00+40.59%
3/3/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$24.00+43.97%
2/8/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$32.00+81.82%
1/26/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$29.00+67.34%
1/9/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$21.00 ➝ $20.00+15.81%
11/2/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$26.00 ➝ $21.00+23.60%
11/2/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$31.00 ➝ $29.00+72.62%
(Data available from 9/24/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












EXEL Price Target - Frequently Asked Questions

What is Exelixis's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Exelixis stock is Moderate Buy based on the current 5 hold ratings and 9 buy ratings for EXEL. The average twelve-month price prediction for Exelixis is $24.73 with a high price target of $32.00 and a low price target of $18.00. Learn more on EXEL's analyst rating history.

Do Wall Street analysts like Exelixis more than its competitors?

Analysts like Exelixis less than other Medical companies. The consensus rating score for Exelixis is 2.64 while the average consensus rating score for medical companies is 2.66. Learn more on how EXEL compares to other companies.

Does Exelixis's stock price have much upside?

According to analysts, Exelixis's stock has a predicted upside of 28.29% based on their 12-month price targets.

What analysts cover Exelixis?

Stock Ratings Reports and Tools

This page (NASDAQ:EXEL) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -